SPECIAL REPORT

7^TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017

Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab

An accumulating body of evidence has indicated that sustained treatment with a disease-modifying therapy (DMT) can improve relapse recovery and slow the accumulation of disability in patients with relapsing MS.